An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression.

Trial Profile

An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2014

At a glance

  • Drugs Danusertib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Nerviano Medical Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Sep 2009 Actual end date (Sep 2010) and actual number of patients (7) added as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top